ArmaGen receives Notice of Allowance from USPTO on broad therapeutic antibody delivery patent
The U.S. Patent and Trademark Office has issued a formal Notice of Allowance for the lead patent in ArmaGen’s platform technology on the delivery across the human blood-brain barrier (BBB) of therapeutic antibodies. Should the BBB drug delivery problem be solved, therapeutic antibodies can be developed as new drugs for multiple brain diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, bovine spongiform encephalopathy, West Nile virus encephalitis, neuro-AIDS, brain injury, spinal cord injury, metastatic cancer of the brain, metastatic breast cancer of the brain, primary cancer of the brain, or multiple sclerosis. The patent entitled “Fusion Antibodies That Cross the Blood-Brain Barrier in Both Directions,” discloses the composition of genetically engineered antibodies that are transported across the BBB via receptor-mediated transport, and bind and inactivate pathologic antigens within the brain. The patent will ultimately provide broad protection for ArmaGen’s portfolio of therapeutic antibodies that have been re-engineered as IgG fusion proteins with receptor-specific molecular Trojan horses that cross the BBB.Therapeutic antibodies, per se, are large molecule drugs that do not cross the BBB. However, following the re-engineering of the therapeutic antibody as an IgG fusion protein with ArmaGen’s molecular Trojan horse, a new chemical entity is created that both crosses the BBB via receptor-mediated transport and retains high affinity binding of the therapeutic antibody for the target antigen in brain.